{"id":"bevacizumab-control","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"15-25","effect":"Proteinuria"},{"rate":"5-15","effect":"Bleeding/hemorrhage"},{"rate":"5-10","effect":"Thromboembolic events"},{"rate":"1-2","effect":"Gastrointestinal perforation"},{"rate":"5-10","effect":"Wound healing complications"},{"rate":"15-20","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, preventing its interaction with VEGF receptors on endothelial cells. This inhibits the formation of new blood vessels that tumors require for growth and metastasis. By starving tumors of their blood supply, bevacizumab slows tumor progression and is typically used in combination with chemotherapy or other targeted agents.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:04.902Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with chemotherapy)"},{"name":"Metastatic non-small cell lung cancer (in combination with chemotherapy)"},{"name":"Metastatic breast cancer (in combination with chemotherapy)"},{"name":"Glioblastoma (recurrent)"},{"name":"Metastatic renal cell carcinoma (in combination with interferon-alpha)"}]},"trialDetails":[{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Triple-Negative Breast Cancer","enrollment":134},{"nctId":"NCT07490262","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2026-03-31","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":680},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT07481786","phase":"PHASE3","title":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Lung Adenocarcinoma, Brain Metastases, Radiotherapy, Intensity-Modulated","enrollment":220},{"nctId":"NCT07481500","phase":"NA","title":"Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","status":"NOT_YET_RECRUITING","sponsor":"Jakkrit Juhong","startDate":"2026-06","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":120},{"nctId":"NCT03842982","phase":"PHASE3","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-05-03","conditions":"Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma","enrollment":362},{"nctId":"NCT05528952","phase":"PHASE2","title":"Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-09-27","conditions":"Hepatocellular Carcinoma","enrollment":105},{"nctId":"NCT02759614","phase":"PHASE3","title":"Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2016-04-01","conditions":"NSCLC","enrollment":311},{"nctId":"NCT07381634","phase":"PHASE2","title":"The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-03-20","conditions":"Hepatocellular Carcinoma (HCC), IrAE","enrollment":134},{"nctId":"NCT07333053","phase":"NA","title":"Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer","status":"RECRUITING","sponsor":"Quanda Liu","startDate":"2026-03-31","conditions":"Unresectable Colorectal Cancer","enrollment":30},{"nctId":"NCT03847428","phase":"PHASE3","title":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-29","conditions":"Hepatocellular Carcinoma","enrollment":908},{"nctId":"NCT06951503","phase":"PHASE3","title":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-27","conditions":"Colorectal Adenocarcinoma","enrollment":560},{"nctId":"NCT06823375","phase":"PHASE2","title":"SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-07-10","conditions":"HCC","enrollment":40},{"nctId":"NCT07228832","phase":"PHASE3","title":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Summit Therapeutics","startDate":"2025-11-18","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":600},{"nctId":"NCT04068610","phase":"PHASE1, PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":61},{"nctId":"NCT05739981","phase":"PHASE1, PHASE2","title":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2023-02-10","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":30},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT07323576","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-02-01","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT07392866","phase":"PHASE2, PHASE3","title":"A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2026-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":120},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT03635567","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-25","conditions":"Cervical Cancer","enrollment":617},{"nctId":"NCT07383285","phase":"PHASE2","title":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02-01","conditions":"Rectal Neoplasms Malignant","enrollment":106},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT04854668","phase":"PHASE3","title":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-05-27","conditions":"Metastatic Colorectal Cancer","enrollment":748},{"nctId":"NCT07370818","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Onconic Therapeutics Inc.","startDate":"2026-02-27","conditions":"Ovarian Cancer","enrollment":81},{"nctId":"NCT07362836","phase":"PHASE3","title":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-31","conditions":"Colorectal Cancer","enrollment":224},{"nctId":"NCT07358520","phase":"PHASE4","title":"Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-28","conditions":"Proteinuria","enrollment":40},{"nctId":"NCT07286695","phase":"PHASE2","title":"Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"Metastatic Colorectal Cancer (CRC), Colorectal Cancer","enrollment":292},{"nctId":"NCT07005570","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）","status":"RECRUITING","sponsor":"Dechang Diao","startDate":"2025-05-01","conditions":"pMMR/MSS Locally Advanced Rectal Cancer","enrollment":86},{"nctId":"NCT03778957","phase":"PHASE3","title":"A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-30","conditions":"Hepatocellular Carcinoma","enrollment":724},{"nctId":"NCT04649489","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jia Fan","startDate":"2021-04-19","conditions":"Venous Thrombosis","enrollment":501},{"nctId":"NCT05337137","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-05-05","conditions":"Carcinoma, Hepatocellular","enrollment":83},{"nctId":"NCT05904886","phase":"PHASE3","title":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-14","conditions":"Hepatocellular Carcinoma","enrollment":687},{"nctId":"NCT00565851","phase":"PHASE3","title":"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-06","conditions":"Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":1052},{"nctId":"NCT07079462","phase":"PHASE2","title":"Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET","enrollment":40},{"nctId":"NCT06791512","phase":"PHASE3","title":"mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC","status":"RECRUITING","sponsor":"Jun Huang","startDate":"2025-01-18","conditions":"Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum","enrollment":166},{"nctId":"NCT03869892","phase":"PHASE3","title":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-03-21","conditions":"Metastatic Colorectal Cancer","enrollment":856},{"nctId":"NCT07293468","phase":"PHASE2, PHASE3","title":"Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)","status":"RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2024-04-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":106},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT06908993","phase":"PHASE3","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-12-09","conditions":"Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation","enrollment":133},{"nctId":"NCT07285850","phase":"PHASE2, PHASE3","title":"The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-10-20","conditions":"HCC - Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT07281664","phase":"NA","title":"Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Hepatocellular Carcinoma, Transarterial Chemoembolization","enrollment":30},{"nctId":"NCT07179900","phase":"PHASE2","title":"Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-12","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT03940690","phase":"PHASE3","title":"Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2019-10-24","conditions":"Retinal Telangiectasis, Coats Disease","enrollment":18},{"nctId":"NCT07261709","phase":"PHASE2","title":"Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-01","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":236},{"nctId":"NCT07058428","phase":"PHASE3","title":"FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2025-06-30","conditions":"Multiple Brain Metastases in Lung Adenocarcinoma","enrollment":258},{"nctId":"NCT07246668","phase":"PHASE2","title":"A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2025-03-10","conditions":"Hepatocellular Carcinoma, Liver Neoplasms, Carcinoma","enrollment":52},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT04982237","phase":"PHASE3","title":"A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2021-08-27","conditions":"Cervical Cancer","enrollment":445},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT07235930","phase":"PHASE3","title":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-15","conditions":"Non-Resectable Pancreas Carcinoma","enrollment":292},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT05053750","phase":"EARLY_PHASE1","title":"TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-14","conditions":"Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":14},{"nctId":"NCT05377034","phase":"PHASE2","title":"Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-10-26","conditions":"Locally Advanced Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT04776655","phase":"PHASE3","title":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","status":"RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-30","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation","enrollment":280},{"nctId":"NCT07198165","phase":"PHASE2","title":"SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-05","conditions":"Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer, Radiotherapy","enrollment":104},{"nctId":"NCT04595266","phase":"PHASE2","title":"Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2021-06-29","conditions":"Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer","enrollment":48},{"nctId":"NCT06008119","phase":"PHASE3","title":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Kechow Pharma, Inc.","startDate":"2023-10-25","conditions":"Colorectal Cancer Metastatic","enrollment":165},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT07150403","phase":"PHASE2","title":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-12-31","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":74},{"nctId":"NCT01189643","phase":"EARLY_PHASE1","title":"Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08","conditions":"Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)","enrollment":15},{"nctId":"NCT03149575","phase":"PHASE3","title":"VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM","status":"TERMINATED","sponsor":"DelMar Pharmaceuticals, Inc.","startDate":"2017-10-27","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":2},{"nctId":"NCT06680258","phase":"PHASE3","title":"A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tempest Therapeutics","startDate":"2025-12","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":740},{"nctId":"NCT07134101","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Colorectal Cancer (Diagnosis)","enrollment":138},{"nctId":"NCT06614192","phase":"PHASE3","title":"A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-11-08","conditions":"Metastatic Colorectal Cancer","enrollment":460},{"nctId":"NCT07134218","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-10","conditions":"Rectal Cancer","enrollment":180},{"nctId":"NCT01951482","phase":"PHASE3","title":"Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Non Squamous Non-small Cell Lung Cancer, Brain Metastases, Bevacizumab","enrollment":160},{"nctId":"NCT06471465","phase":"PHASE3","title":"Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases","status":"RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2025-04-29","conditions":"Radionecrosis of Brain, Brain Metastases","enrollment":84},{"nctId":"NCT06109272","phase":"PHASE2, PHASE3","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-01-11","conditions":"Hepatocellular Carcinoma","enrollment":660},{"nctId":"NCT06856187","phase":"PHASE2","title":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-28","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":119},{"nctId":"NCT05480306","phase":"PHASE2","title":"Phase 2 Study of DKN-01 in Colorectal Cancer","status":"COMPLETED","sponsor":"Leap Therapeutics, Inc.","startDate":"2022-08-30","conditions":"Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer","enrollment":188},{"nctId":"NCT06841172","phase":"PHASE3","title":"Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-21","conditions":"OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy","enrollment":132},{"nctId":"NCT07093762","phase":"","title":"Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Fuzhou General Hospital","startDate":"2025-08-20","conditions":"Non Small Cell Lung Cancer","enrollment":35},{"nctId":"NCT06865521","phase":"NA","title":"Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2025-02-21","conditions":"Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila","enrollment":22},{"nctId":"NCT07090525","phase":"PHASE2","title":"Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2025-07-01","conditions":"Overall Response Rate","enrollment":60},{"nctId":"NCT07075562","phase":"NA","title":"TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2021-06-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":180},{"nctId":"NCT07071844","phase":"PHASE2","title":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-09","conditions":"Metastatic Colorectal Cancer","enrollment":162},{"nctId":"NCT07051785","phase":"PHASE2","title":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Liu Huang","startDate":"2025-07-07","conditions":"Colorectal Cancer (CRC)","enrollment":68},{"nctId":"NCT06954584","phase":"PHASE3","title":"Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-05-27","conditions":"Ovarian Cancer","enrollment":424},{"nctId":"NCT07021950","phase":"PHASE2","title":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-10","conditions":"Colorectal Cancer, Ivonescimab","enrollment":130},{"nctId":"NCT04406272","phase":"PHASE2","title":"VB-111 in Surgically Accessible Recurrent/Progressive GBM","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":15},{"nctId":"NCT07002346","phase":"PHASE3","title":"INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Clear Cell Carcinoma","enrollment":226},{"nctId":"NCT06999148","phase":"PHASE2","title":"Study on The Sensitizing Effect of Sonodynamic Therapy on The Treatment of Brainstem Glioma With Radiotherapy and Chemotherapy and Survival Analysis","status":"ENROLLING_BY_INVITATION","sponsor":"Yingjuan Zheng","startDate":"2024-10-01","conditions":"Glioma (Any Grade) in the Brain","enrollment":216},{"nctId":"NCT06280495","phase":"PHASE2, PHASE3","title":"Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-02-01","conditions":"Colorectal Cancer, Liver Metastases","enrollment":156},{"nctId":"NCT05727163","phase":"PHASE2","title":"FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-07-29","conditions":"Colorectal Cancer Metastatic","enrollment":194},{"nctId":"NCT06992648","phase":"PHASE3","title":"Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-01","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Recurrent","enrollment":302},{"nctId":"NCT06982924","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-06-30","conditions":"EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive","enrollment":136},{"nctId":"NCT04856787","phase":"PHASE2, PHASE3","title":"A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-06-22","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":62},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT06618664","phase":"PHASE3","title":"Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-10-28","conditions":"Advanced Hepatocellular Carcinoma","enrollment":590},{"nctId":"NCT06459687","phase":"PHASE3","title":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Lee's Pharmaceutical Limited","startDate":"2024-11-28","conditions":"Cervical Cancer","enrollment":440},{"nctId":"NCT06971237","phase":"","title":"SIRT and Peri-immunotherapy : a New Concept","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-06-01","conditions":"Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy","enrollment":60},{"nctId":"NCT02394834","phase":"","title":"An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":757},{"nctId":"NCT00696592","phase":"PHASE2","title":"Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration","status":"WITHDRAWN","sponsor":"University of Padova","startDate":"2007-01-31","conditions":"Neovascular Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT06555003","phase":"PHASE3","title":"DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases","status":"RECRUITING","sponsor":"Tehran University of Medical Sciences","startDate":"2025-01-20","conditions":"Liver Neoplasm, Colorectal Cancer Metastatic","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3266,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bevacizumab control","genericName":"Bevacizumab control","companyName":"Institut de Recherches Internationales Servier","companyId":"institut-de-recherches-internationales-servier","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer (in combination with chemotherapy), Metastatic non-small cell lung cancer (in combination with chemotherapy), Metastatic breast cancer (in combination with chemotherapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}